Hertel P, Lindblom N, Nomikos G G, Svensson T H
Department of Physiology and Pharmacology, Karolinska Institutet, Stockolm, Sweden.
Psychopharmacology (Berl). 2001 Jan;153(3):307-14. doi: 10.1007/s002130000582.
The present study was undertaken to characterize the regulation of serotonin (5-HT) efflux and neuronal activity in the dorsal raphe nucleus (DRN) as well as to examine the potential ability of the antipsychotic drug risperidone to interfere with these mechanisms.
By using microdialysis in freely moving rats, it was found that administration of the alpha2 adrenoceptor antagonist idazoxan (0.25 mg/kg, SC), the 5-HT1B/D receptor antagonist GR 127,935 (1.0 mg/kg, SC) and risperidone (0.6 or 2.0 mg/kg, SC) increased 5-HT output in the DRN. Local DRN perfusion with GR 127,935 or risperidone via reversed dialysis (100 or 10-100 microM, respectively) enhanced 5-HT efflux in this area, whereas idazoxan (10-100 microM) failed to affect this parameter. Both systemic administration and reversed DRN dialysis of the D2/3 and 5-HT2A receptor antagonists raclopride (2.0 mg/kg, SC or 10-100 microM) and MDL 100,907 (1.0 mg/kg, SC or 10-100 microM), respectively, were without effect. Intraraphe dialysis of the 5-HT1B/D receptor agonist CP 135,807 (0.2 microM) decreased the efflux of 5-HT in the DRN, an effect which was antagonized by co-administration of either GR 127,935 or risperidone (10 and 3.3 microM, respectively). By using single-cell recording, it was found that administration of GR 127,935 (50-400 microg/kg, IV) decreased, whereas CP 135,807 (2.5-20 microg/kg, IV) increased firing of 5-HT cells in the DRN.
Our findings suggest a regulatory role of local 5-HT1B/D receptors on 5-HT efflux as well as cell firing in the DRN and indicate that risperidone may interfere with the regulation of 5-HT availability in this area primarily via blockade of 5-HT1D receptors.
开展本研究以表征中缝背核(DRN)中5-羟色胺(5-HT)流出及神经元活动的调节机制,并检验抗精神病药物利培酮干扰这些机制的潜在能力。
通过对自由活动的大鼠进行微透析发现,给予α2肾上腺素能受体拮抗剂伊达唑烷(0.25mg/kg,皮下注射)、5-HT1B/D受体拮抗剂GR 127,935(1.0mg/kg,皮下注射)和利培酮(0.6或2.0mg/kg,皮下注射)可增加DRN中5-HT的输出量。通过反向透析分别用GR 127,935或利培酮(分别为100或10 - 100μM)对DRN进行局部灌注可增强该区域的5-HT流出,而伊达唑烷(10 - 100μM)未能影响该参数。D2/3和5-HT2A受体拮抗剂雷氯必利(2.0mg/kg,皮下注射或10 - 100μM)和MDL 100,907(1.0mg/kg,皮下注射或10 - 100μM)的全身给药及DRN反向透析均无效果。向中缝内透析5-HT1B/D受体激动剂CP 135,807(0.2μM)可降低DRN中5-HT的流出,这一效应可被同时给予GR 127,935或利培酮(分别为10和3.3μM)所拮抗。通过单细胞记录发现,给予GR 127,935(50 - 400μg/kg,静脉注射)可降低DRN中5-HT细胞的放电频率,而给予CP 135,807(2.5 - 20μg/kg,静脉注射)则可增加其放电频率。
我们的研究结果表明局部5-HT1B/D受体对DRN中5-HT流出及细胞放电具有调节作用,并表明利培酮可能主要通过阻断5-HT1D受体来干扰该区域5-HT可用性的调节。